Trials / Completed
CompletedNCT03573960
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Lenvatinib capsules. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
- First posted
- 2018-06-29
- Last updated
- 2026-03-06
Locations
11 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03573960. Inclusion in this directory is not an endorsement.